The Leukodystrophies drugs in development market research report provides comprehensive information on the therapeutics under development for Leukodystrophies, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Leukodystrophies. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Leukodystrophies and features dormant and discontinued products.
GlobalData tracks 27 drugs in development for Leukodystrophies by 23 companies/universities/institutes. The top development phase for Leukodystrophies is preclinical with 15 drugs in that stage. The Leukodystrophies pipeline has 22 drugs in development by companies and five by universities/ institutes. Some of the companies in the Leukodystrophies pipeline products market are: Contera Pharma, Myrtelle and Ionis Pharmaceuticals.
The key targets in the Leukodystrophies pipeline products market include Arylsulfatase A, Myelin Proteolipid Protein, and Tubulin Beta 4A Chain.
The key mechanisms of action in the Leukodystrophies pipeline product include Arylsulfatase A Activator with six drugs in Phase II. The Leukodystrophies pipeline products include four routes of administration with the top ROA being Intravenous and eight key molecule types in the Leukodystrophies pipeline products market including Gene Therapy, and Cell Therapy.
Leukodystrophies overview
Leukodystrophies, a collection of rare genetic disorders impacting the central nervous system (CNS), specifically the brain and spinal cord, cause damage to the CNS’s white matter. This damage hampers or obstructs signals between nerve cells, resulting in varied symptoms such as movement difficulties, vision and hearing impairment, and cognitive challenges. Due to the multitude of leukodystrophy types with differing symptoms, diagnosis poses a challenge. Healthcare providers employ physical and neurological exams, medical history inquiries, imaging tests like MRI or CT scans, genetic testing, and lab tests to diagnose. While no cure exists, treatment concentrates on symptom relief and support, encompassing medications, therapies, and nutritional and educational interventions.
For a complete picture of Leukodystrophies’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
